Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Michael T Tetzlaff

Showing results (101-110 of 224) with videos related to

Pageof 23
Sort By:
Melanoma Research|October 22, 2016
High cytotoxic T-lymphocyte-associated antigen 4 and phospho-Akt expression in tumor samples predicts poor clinical outcomes in ipilimumab-treated melanoma patientsNitin Chakravarti, Doina Ivan, Van A Trinh, et al.
Ophthalmic Plastic and Reconstructive Surgery|October 30, 2018
Pathological Features and Clinical Course in Patients With Recurrent or Malignant Orbital Solitary Fibrous Tumor/HemangiopericytomaOded Sagiv, Diana Bell, Yunxia Guo, et al.
Journal of Cutaneous Pathology|April 20, 2018
Metastatic melanoma with balloon/histiocytoid cytomorphology after treatment with immunotherapy: A histologic mimic and diagnostic pitfallMaya Farah, Priyadharsini Nagarajan, Carlos A Torres-Cabala, et al.
Oncotarget|February 1, 2018
Hypoxia-activated prodrug enhances therapeutic effect of sunitinib in melanomaShujing Liu, Michael T Tetzlaff, Tao Wang, et al.
Human Pathology|March 31, 2018
Intratumoral and peritumoral lymphovascular invasion detected by D2-40 immunohistochemistry correlates with metastasis in primary cutaneous Merkel cell carcinomaRami N Al-Rohil, Denái R Milton, Priyadharsini Nagarajan, et al.
The American Journal of Dermatopathology|January 31, 2017
Lichenoid Dermatologic Toxicity From Immune Checkpoint Blockade Therapy: A Detailed Examination of the Clinicopathologic FeaturesMichael T Tetzlaff, Priyadharsini Nagarajan, Susan Chon, et al.
The American Journal of Dermatopathology|June 21, 2014
Histological features associated with vemurafenib-induced skin toxicities: examination of 141 cutaneous lesions biopsied during therapyJonathan L Curry, Michael T Tetzlaff, Kimberly Nicholson, et al.
International Journal of Dermatology|November 21, 2017
Regressed melanocytic nevi secondary to pembrolizumab therapy: an emerging melanocytic dermatologic effect from immune checkpoint antibody blockadeShakuntala H Mauzo, Michael T Tetzlaff, Kelly Nelson, et al.
JAMA Ophthalmology|July 24, 2015
Distinct pathways in the pathogenesis of sebaceous carcinomas implicated by differentially expressed microRNAsMichael T Tetzlaff, Jonathan L Curry, Vivian Yin, et al.
Journal of Cutaneous Pathology|August 13, 2016
Cutaneous histoplasmosis with prominent parasitization of epidermal keratinocytes: report of a caseHedieh H Honarpisheh, Jonathan L Curry, Kristen Richards, et al.
Pageof 23

Showing results (101-110 of 224) with videos related to

Sort By:
Pageof 23
Melanoma Research|October 22, 2016
High cytotoxic T-lymphocyte-associated antigen 4 and phospho-Akt expression in tumor samples predicts poor clinical outcomes in ipilimumab-treated melanoma patientsNitin Chakravarti, Doina Ivan, Van A Trinh, et al.
Ophthalmic Plastic and Reconstructive Surgery|October 30, 2018
Pathological Features and Clinical Course in Patients With Recurrent or Malignant Orbital Solitary Fibrous Tumor/HemangiopericytomaOded Sagiv, Diana Bell, Yunxia Guo, et al.
Journal of Cutaneous Pathology|April 20, 2018
Metastatic melanoma with balloon/histiocytoid cytomorphology after treatment with immunotherapy: A histologic mimic and diagnostic pitfallMaya Farah, Priyadharsini Nagarajan, Carlos A Torres-Cabala, et al.
Oncotarget|February 1, 2018
Hypoxia-activated prodrug enhances therapeutic effect of sunitinib in melanomaShujing Liu, Michael T Tetzlaff, Tao Wang, et al.
Human Pathology|March 31, 2018
Intratumoral and peritumoral lymphovascular invasion detected by D2-40 immunohistochemistry correlates with metastasis in primary cutaneous Merkel cell carcinomaRami N Al-Rohil, Denái R Milton, Priyadharsini Nagarajan, et al.
The American Journal of Dermatopathology|January 31, 2017
Lichenoid Dermatologic Toxicity From Immune Checkpoint Blockade Therapy: A Detailed Examination of the Clinicopathologic FeaturesMichael T Tetzlaff, Priyadharsini Nagarajan, Susan Chon, et al.
The American Journal of Dermatopathology|June 21, 2014
Histological features associated with vemurafenib-induced skin toxicities: examination of 141 cutaneous lesions biopsied during therapyJonathan L Curry, Michael T Tetzlaff, Kimberly Nicholson, et al.
International Journal of Dermatology|November 21, 2017
Regressed melanocytic nevi secondary to pembrolizumab therapy: an emerging melanocytic dermatologic effect from immune checkpoint antibody blockadeShakuntala H Mauzo, Michael T Tetzlaff, Kelly Nelson, et al.
JAMA Ophthalmology|July 24, 2015
Distinct pathways in the pathogenesis of sebaceous carcinomas implicated by differentially expressed microRNAsMichael T Tetzlaff, Jonathan L Curry, Vivian Yin, et al.
Journal of Cutaneous Pathology|August 13, 2016
Cutaneous histoplasmosis with prominent parasitization of epidermal keratinocytes: report of a caseHedieh H Honarpisheh, Jonathan L Curry, Kristen Richards, et al.
Pageof 23